Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer

International Journal of Biological Markers

Volumn 22, Issue 1, 2007, Pages 12-18

  Symvoulakis, E K ^a   Zaravinos, A ^a   Panutsopulos, D ^a   Zoras, O ^a   Papalambros, E ^b   Sigala, F ^b   Spandidos, D A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colorectal cancer; Exon 15 BRAF; KRAS codon 12 mutations; Mutational analysis; Restriction fragment length polymorphism; V600E

Indexed keywords

B RAF KINASE; DNA; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CODON; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC CONSERVATION; GREECE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 34248368818     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1785     Document Type: Article

References (44)

1. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002; 64: 1-25.
2. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002; 64: 27-43.
3. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004; 127: 1578-88.
4. Kiaris H, Spandidos DA. Mutations of ras genes in human tumours. Int J Oncol 1995; 7: 413-21.
5. Zachos G, Spandidos DA. Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Crit Rev Oncol Hematol 1997; 26: 65-75.
6. Zauber NP, Sabbath-Solitare M, Marotta SP, Bishop DT. K-ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma. Cancer 1999; 86: 31-6.
7. Spandidos DA, Sourvinos G, Tsatsanis C, Zafiropoulos A. Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int J Oncol 2002; 21: 237-41.
8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
9. Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996; 23: 118-34.
10. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351: 289-305.
11. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53-62.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
13. Helmke BM, Mollenhauer J, Herold-Mende C, et al. BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. Gastroenterology 2004; 127: 1815-20.
14. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
15. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
16. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and K-RAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-5.
17. Lineweaver W. Staging of colon cancer. Contemp Surg 1984; 25: 19.
18. Glarakis IS, Savva S, Spandidos DA. Activation of the ras genes in malignant and premalignant colorectal tumors. Oncol Rep 1998; 5: 1451-4.
19. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 2004; 18: 349-52.
20. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, lacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
21. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63: 5209-12.
22. Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 2005; 20: 115: 943-50.
23. Panagopoulos I, Mertens F, Isaksson M, Mandhal N. Absence of mutations of BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet Cytogenet 2005; 156: 74-6.
24. Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003; 21: 327-30.
25. Edwards RH, Ward MR, Wu H, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004; 41: 270-2.
26. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RAS-CAL II' study. Br J Cancer 2001; 85: 692-6.
27. Yuen ST, Chung LP, Leung SY, et al. Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. Br J Cancer 1997; 76: 1610-6.
28. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-7.
29. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
30. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-46.
31. Arun C, London NJM, Hemingway DM. Prognostic significance of elevated endothelin-1 levels in patients with colorectal cancer. Int J Biol Markers 2004; 19: 32-7.
32. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
33. Minoo P, Jass JR. Senescence and serration: a new twist to an old tale. J Pathol. 2006; 210(2): 137-40.
34. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004; 22: 4584-94.
35. Domingo E, Espin E, Armengol M, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-42.
36. Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004; 108: 237-42.
37. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65: 6063-9.
38. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hy-permethylation frequency and BRAF mutations distinguish hereditary nonpolyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004, 3: 101-7.
39. Miyaki M, Iijima T, Yamaguchi T, Kadofuku T, Funata N, Mori T. Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. Cancer Lett 2004, 211: 105-9.
40. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004, 41: 664-8.
41. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24: 3995-8.
42. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-8.
43. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007; 120: 656-63.
44. Bernardo CG, Gonzalez JJ, Sanz L, et al. Mismatch repair protein MSH2 expression and prognosis of colorectal cancer patients. Int J Biol Markers 2004; 19: 190-5.